PF-Atlas › Treatments › Admilparant / BMS-986278

Admilparant / BMS-986278

LPA1 receptor antagonist — blocks lysophosphatidic acid pro-fibrotic signaling

Clinically established — FDA-approved or positive Phase III. How PF-Atlas grades evidence.
Development stage
Phase III (ALOFT-IPF)
Evidence level
Level 1 (Phase III)
Mechanism class
LPA1 receptor antagonist — blocks lysophosphatidic acid pro-fibrotic signaling
Timeline
1-2 years
Risk profile
Low-Medium
Developer
Bristol-Myers Squibb
Key researchers
T. Maher

Overview

Phase II: 60mg delayed disease progression vs placebo in IPF and PPF. ALOFT-IPF Phase III completing Oct 2026. Novel mechanism orthogonal to nintedanib/pirfenidone. Oral, once daily.

How Admilparant / BMS-986278 fits into IPF treatment

Admilparant / BMS-986278 is classified as Level 1 (Phase III) at the Phase III (ALOFT-IPF) stage. Explore how it compares to other options and where it sits in the development pipeline:

Admilparant drug profileLPA1 receptor antagonist — blocks lysophosphatidic acid pro-fibrotic signalingClinical trialsDrug pipelineResearch

Other IPF treatments

Nerandomilast / JascaydInhaled Treprostinil / TyvasoRentosertib / ISM001-055AI Knowledge GraphuPAR-CAR-T Senolytic ImmunotherapySenolytics + WNT Agonist Combination
Medical disclaimer. This page summarizes published research and PF-Atlas model output about Admilparant / BMS-986278 for information only. It is not medical advice or a treatment recommendation. Drug availability, approval status and evidence change — verify with a pulmonologist and official sources (FDA, ClinicalTrials.gov) before any decision.